Business

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Financial Post · August 26, 2026 at 4:03 p.m.

VANCOUVER, BC and BOSTON, MA, Aug.

26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16 th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

More from Financial Post

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026

Snow Alert: It’s Snowing in Ikon Pass Country

William Watson: Let’s see the last draft. Inquiring voters want to know

Opinion: We need to reduce wildfire fuel and zone better

More in Business

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026

Snow Alert: It’s Snowing in Ikon Pass Country

Old soup factory takes on new high-tech life as quantum computing firm gets $195M federal boost

William Watson: Let’s see the last draft. Inquiring voters want to know

Opinion: We need to reduce wildfire fuel and zone better

Zacatecas Silver Closes the Second Tranche of Non-Brokered Private Placement